Hinge Health (HNGE) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
8 Aug, 2026Executive summary
Q2 2026 delivered record financial results with revenue of $213 million, up 53% year-over-year, and free cash flow reaching $100 million, driven by strong enterprise and SMB performance, product expansion into migraine and GI care, and the acquisition of Cylinder Health for $105 million.
The company expanded its client base to 2,929 as of June 30, 2026, with LTM calculated billings of $862 million, and launched new programs including Migraine Care and GI Care.
Multi-product strategy is deepening client relationships, driving higher engagement, and expanding total addressable market.
Board approved a $300 million increase to the share repurchase program, bringing total authorization to $496.5 million.
Financial highlights
Q2 2026 revenue: $213 million (53% YoY growth); GAAP gross margin: 86% (up from 70%); Non-GAAP gross margin: 87% (up from 83%).
Operating income more than doubled to $62 million, with non-GAAP operating margin expanding to 29% from 19% year-over-year.
Free cash flow was $100 million (47% margin), up from $33 million (23% margin) in Q2 2025.
Ended Q2 with $476 million in cash and equivalents; repurchased $196.5 million of Class A shares as of July 29, 2026.
Net income for Q2 2026 was $43.7 million, a turnaround from a net loss of $575.7 million in Q2 2025.
Outlook and guidance
Q3 2026 revenue guidance: $223–$225 million (45% YoY growth midpoint); non-GAAP income from operations $61–$63 million; non-GAAP operating margin 28%.
Full-year 2026 revenue guidance raised to $856–$860 million (46% YoY growth midpoint); non-GAAP income from operations $236–$244 million (28% margin midpoint).
Cylinder Health expected to contribute $7–$8 million in revenue for the remainder of 2026, with greater impact in 2027 and beyond.
Management expects continued revenue growth driven by client and member expansion, new product launches, and integration of Cylinder Health.
Expects to maintain strong liquidity with $286.2 million in cash and $187.9 million in marketable securities as of June 30, 2026.
Latest events from Hinge Health
- 2026 revenue guidance raised to $818–$824M with 27% operating margin expected.HNGE
Investor Day 2026 - Directors were elected and Deloitte was ratified as auditor, with all proposals approved.HNGE
AGM 2026 - Q1 2026 revenue rose 47% to $182.3M, margins expanded, and guidance was raised.HNGE
Q1 2026 - Vote virtually by June 3, 2026, on director elections and auditor ratification.HNGE
Proxy filing - Director elections, auditor ratification, and strong governance with equity-focused compensation.HNGE
Proxy filing - Record 2025 revenue, margins, and client growth, with strong 2026 outlook and share buybacks.HNGE
Q4 2025 - IPO highlights strong growth, high retention, and tech-driven MSK care with dual-class structure.HNGE
Registration Filing - AI-driven MSK care platform posts 33% revenue growth, strong margins, and targets global expansion.HNGE
Registration Filing - IPO targets $230M+ net proceeds, strong growth, but most funds go to RSU tax obligations.HNGE
Registration Filing